Table 1 Clinicopathological characteristics before and after PSM
Before PSM | After PSM | |||||
|---|---|---|---|---|---|---|
Wide | Narrow | P-Value | Wide | Narrow | P-Value | |
(n = 195) | (n = 283) | (n = 79) | (n = 79) | |||
Gender | ||||||
Male | 103 (52.8%) | 184 (65.0%) | 0.010 | 51 (64.6%) | 47 (59.5%) | 0.623 |
Female | 92 (47.2%) | 99 (35.0%) | 28 (35.4%) | 32 (40.5%) | ||
Age | ||||||
≤ 60 years | 115(59.0%) | 177(62.5%) | 0.489 | 42(53.2%) | 50(63.3%) | 0.259 |
> 60 years | 80(41.0%) | 106(7.5%) | 37(46.8%) | 29(36.7%) | ||
HBsAg | ||||||
Negative | 144 (73.8%) | 184 (65.0%) | 0.052 | 55(69.6%) | 59(74.7%) | 0.594 |
Positive | 51 (26.2%) | 99 (35.0%) | 24(30.4%) | 20(25.3%) | ||
CA19–9 | ||||||
≤ 200 U/mL | 136 (69.7%) | 253 (89.4%) | < 0.001 | 63(79.7%) | 65(82.3%) | 0.839 |
> 200 U/mL | 59 (30.3%) | 30 (10.6%) | 16(20.3%) | 14(17.7%) | ||
CEA | ||||||
≤ 5 μg/L | 125 (64.1%) | 234 (82.7%) | < 0.001 | 56(70.9%) | 56(70.9%) | 1.000 |
> 5 μg/L | 70 (35.9%) | 49 (17.3%) | 23(29.1%) | 23(29.1%) | ||
Blood loss | ||||||
≤ 400 mL | 141(72.3%) | 229(80.9%) | 0.036 | 61(77.2%) | 57(72.2%) | 0.583 |
>400 mL | 54(27.7%) | 54(19.1%) | 18(22.8%) | 22(27.8%) | ||
Transfusion | ||||||
No | 148(75.9%) | 246(86.9%) | 0.003 | 60(75.9%) | 61(77.2%) | 1.000 |
Yes | 47(24.1%) | 37(13.1%) | 19(24.1%) | 18(22.8%) | ||
Laparoscopic approach | ||||||
No | 163 (83.6%) | 281 (99.3%) | < 0.001 | 76 (96.2%) | 77 (97.5%) | 1.000 |
Yes | 32 (16.4%) | 2 (0.7%) | 3 (3.8%) | 2 (2.5%) | ||
Major hepatectomy | ||||||
No | 72 (36.9%) | 80 (28.3%) | 0.058 | 32(40.5%) | 31(39.2%) | 1.000 |
Yes | 123 (63.1%) | 203(71.7%) | 47(59.5%) | 48(60.8%) | ||
Complications | ||||||
No | 137 (70.3%) | 233 (82.3%) | 0.003 | 60 (75.9%) | 59 (74.7%) | 1.000 |
Yes | 58 (29.7%) | 50 (17.7%) | 19 (24.1%) | 20 (25.3%) | ||
Tumor size | ||||||
≤ 5 cm | 86 (44.1%) | 94 (33.2%) | 0.020 | 37(46.8%) | 34(43.0%) | 0.749 |
> 5 cm | 109 (55.9%) | 189 (66.8%) | 42(53.2%) | 45(57.0%) | ||
Tumor number | ||||||
Single | 163 (83.6%) | 181 (64.0%) | < 0.001 | 61(77.2%) | 60(75.9%) | 1.000 |
Multiple | 32 (16.4%) | 102 (36.0%) | 18(22.8%) | 19(24.1%) | ||
Lymph node invasion | ||||||
No | 140 (71.8%) | 250 (88.3%) | < 0.001 | 67 (84.8%) | 69 (87.3%) | 0.818 |
Yes | 55 (28.2%) | 33 (11.7%) | 12 (15.2%) | 10 (12.7%) | ||
Mass-forming | ||||||
No | 38 (19.5%) | 116 (41.0%) | < 0.001 | 28(35.4%) | 19(24.1%) | 0.164 |
Yes | 157 (80.5%) | 167 (59.0%) | 51(64.6%) | 60(75.9%) | ||
Tumor differentiation | ||||||
Well &Moderate | 139 (71.3%) | 236 (83.4%) | 0.002 | 64(81.0%) | 60(75.9%) | 0.561 |
Poor | 56 (28.7%) | 47 (16.6%) | 15(19.0%) | 19(24.1%) | ||
Satellite | ||||||
No | 170 (87.2%) | 181 (64.0%) | < 0.001 | 65(82.3%) | 62(78.5%) | 0.689 |
Yes | 25 (12.8%) | 102 (36.0%) | 14(17.7%) | 17(21.5%) | ||
MVI | ||||||
No | 165 (84.6%) | 254 (89.8%) | 0.124 | 72(91.1%) | 68(86.1%) | 0.453 |
Yes | 30 (15.4%) | 29 (10.2%) | 7(8.9%) | 11(13.9%) | ||
Perineural invasion | ||||||
No | 164 (84.1%) | 261 (92.2%) | 0.008 | 66(83.5%) | 69(87.3%) | 0.652 |
Yes | 31 (15.9%) | 22 (7.8%) | 13(16.5%) | 10(12.7%) | ||
p-AT | ||||||
No | 141(72.3%) | 240(84.8%) | 0.001 | 64(81.0%) | 66(83.5%) | 0.835 |
Yes | 54(27.7%) | 43(15.2%) | 15(19.0%) | 13(16.5%) | ||